Compare GOVX & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOVX | XAIR |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 3.0M |
| IPO Year | 1996 | 2015 |
| Metric | GOVX | XAIR |
|---|---|---|
| Price | $0.17 | $2.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $10.00 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 111.0K | 26.3K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,489,145.00 | ★ $7,679,000.00 |
| Revenue This Year | N/A | $4.23 |
| Revenue Next Year | N/A | $108.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 107.26 |
| 52 Week Low | $0.17 | $0.33 |
| 52 Week High | $1,425.00 | $8.19 |
| Indicator | GOVX | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 8.96 | 40.08 |
| Support Level | N/A | $2.05 |
| Resistance Level | $8.64 | $3.30 |
| Average True Range (ATR) | 0.16 | 0.16 |
| MACD | -0.15 | 0.06 |
| Stochastic Oscillator | 0.00 | 34.48 |
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.